Endocrinology

INTRODUCTION

Diabetic retinopathy is the primary cause of blindness in 20-64 years old. Recent studies support that patients with diabetes after 10-15 years will develop diabetic retinopathy or have some degree of retinal damage.  The treatment options mainly focus on the last stages of the disease. Although it is a  health challenge, science is lagging in treatment options, especially, for the early stages of the disease where the excessive blood glucose damages the vessels walls and leads to gradual degeneration of the vessels increasing the oxidative stress and activating the inflammation.

In addition to diabetic retinopathy, patients with diabetes have an increased risk of developing vein occlusion. Although, in this particular case atherosclerosis is the most common cause. In vein occlusion, the retinal vein is blocked, preventing normal blood flow and leading to inflammation.

PRODUCT INFORMATION

Retinoaspis is a formulation with ingredients that contribute to the better management of diabetic retinopathy and retinal vein occlusion.

Its components support the metabolism, structure and function of retinal cells. They offer a strong anti-inflammatory effect by promoting the production of anti-inflammatory cytokines.    A key anti-inflammatory component is docosahexaenoic acid (DHA)* which is a necessary component for the body’s function and cannot synthesize itself. Retinoaspis also includes components with antioxidant activity, thus providing the necessary antioxidant mechanism to the retina. Astaxanthin, contained in the product, is literally hundreds of times stronger than other antioxidant molecules.  Astaxanthin comes from the algae Haematococcus pluvialis and is a natural carotenoid. Retinoaspis includes vitamin B12, which covers the body's vitamin needs, regulates homocysteine ​​levels* and also provides anti-inflammatory effect.

 *Health claims according to (EU) Regulation 432/2012: DHA contributes to the maintenance of normal vision. Vitamin B12 contributes to normal homocysteine metabolism.

INTRODUCTION

Graves’ disease, also known as thyroid eye disease, is an autoimmune disease in which, for unknown reason, the immune system attacks to healthy tissue in thyroid gland. Its name comes from the Irish doctor Robert Graves who was the first to identify the disease. In Graves’ disease the thyroid gland produces an excess of thyroid hormone. Graves’ disease is the most common cause of hyperthyroidism and it mainly affects people aged 30–50, but it can also affect children and older people. Graves’ disease can affect the heart, bones, liver and skin. Existing treatment options focus on regulation of thyroid hormone levels. This disease can also cause eye disease symptoms, such as bulging, irritated eyes, swelling tissues around the eyes, light sensitivity, pressure and pain, double and blurred vision.

PRODUCT INFORMATION

Eyeaspis DE-Caps is a product, which includes ingredients that help to manage dry eye disease and decongest the meibomian gland. The ingredients of Eyeaspis DE-Caps offer proven anti-inflammatory action, as well as the main substance of fatty acid in the meibomian gland to produce the right quality and quantity of the lipid layer (meibum).

Key components of the lipid layer with a strong anti-inflammatory effect are ω-3 fatty acids, such as eicosapentaenoic acid (EPA), which is an essential fatty acid for the functions of the body and which the body is unable to synthesize on its own.

Eyeaspis DE-Caps includes its main ingredient EPA in form of re-esterified triglycerides with anti-inflammatory action, as well as maqui berry extract, with antioxidant action (35% delphinidins). In addition, it contains Vitamin D3 and Vitamin B12 both of which cover the basic needs of the body.

Coming Soon!